TABLE 2.
Univariate analysis: Summary of effects of different coviarates on survival.
| Summary of effects of different covariates on survival (n = 182) | |||
|---|---|---|---|
| Hazard ratio | p-value | ||
| Demographics | Male | 1.10 (0.72–1.67) | 0.668 |
| Age | 1.00 (0.99–1.02) | 0.742 | |
| Body mass index | 0.98 (0.94–1.02) | 0.344 | |
| Surgical Procedure | |||
| BSLTx | 0.98 (0.56–1.73) | 0.954 | |
| SLTx | 0.84 (0.47–1.52) | 0.566 | |
| Diagnosis | Cystic Fibrosis | 0.81 (0.50–1.34) | 0.422 |
| Chronic obstructive pulmonary disease | 1.25 (0.83–1.90) | 0.290 | |
| Interstitial lung disease | 0.87 (0.51–1.48) | 0.610 | |
| Pulmonary Hypertension | 0.51 (0.22–1.18) | 0.118 | |
| Retransplant | 1.49 (0.43–5.12) | 0.53 | |
| Other | 2.08 (0.84–5.16) | 0.113 | |
| Everolimus | Use of EVE | 1.15 (0.75–1.76) | 0.514 |
| Time of Transplant to Initiation | 0.99 (0.98–0.99) | <0.0001 | |
| Discontinuation of EVE | 1.99 (1.11–3.54) | 0.020 | |
| Indication for EVE | 0.91 (0.56–1.47) | 0.699 | |
| EVE Level | 1.06 (0.96–1.16) | 0.282 | |
| Immunosuppression a | Tacrolimus | 1.32 (0.79–2.19) | 0.290 |
| Ciclosporin | 0.83 (0.48–1.42) | 0.492 | |
| Azathioprine | 1.14 (0.75–1.72) | 0.542 | |
| Mycophenolate | 0.62 (0.39–0.99) | 0.047 | |
| Indication | Renal preservation | 1.65 (0.87–3.12) | 0.128 |
| CLAD | Existence of CLAD b | 3.73 (2.06–6.75) | <0.0001 |
| CLAD phenotype | 0.59 (0.36–0.96) | 0.033 | |
| CLAD at time of starting EVE | 0.84 (0.39–1.82) | 0.657 | |
| FER at diagnosis of CLAD | 0.98 (0.96–0.98) | 0.024 | |
| Azithromycin prophylaxis | 0.52 (0.30–0.91) | 0.019 | |
| Spirometry | FEV1: Time of starting EVE (measured) | 0.70 (0.56–0.87) | 0.002 |
| FEV1: Time of starting EVE (percentage) | 0.98 (0.97–0.99) | 0.0001 | |
| FVC: Time of starting EVE (measured) | 0.79 (0.66–0.96) | 0.018 | |
| FVC: Time of starting EVE (percentage) | 0.98 (0.98–0.99) | 0.005 | |
| FEV1:1-year post starting EVE (measured) | 0.49 (0.36–0.66) | <0.0001 | |
| FEV1:1-year post starting EVE (percentage) | 0.97 (0.96–0.98) | <0.0001 | |
| FVC: 1-year post starting EVE (measured) | 0.69 (0.53–0.90) | 0.006 | |
| FVC: 1-year post starting EVE (percentage) | 0.97 (0.96–0.98) | <0.0001 | |
| Cytomegalovirus | Cytomegalovirus reactivation c | 1.33 (0.84–2.08) | 0.219 |
Abbreviations: BSLTx, bilateral sequential lung transplant; CLAD, chronic lung allograft dysfunction; EVE, everolimus; FER, forced expiratory ratio; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SLTx, single lung transplant.
a
Maintenance immunosuppression at time of starting EVE.
b
Diagnosis of BOS or RAS pre or post starting EVE.
c
Cytomegalovirus reactivation post starting EVE.